G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that familiar routine of relentless meetings, deadlines, and the like has returned. You knew this would happen, though, yes? This calls for a much-needed cup of stimulation. Our flavor today is vanilla macadamia nut, for those keeping track. Please do join us. Remember that no prescription is required. Meanwhile, here are some tidbits. Hope you have a smashing day and do keep in touch …

Pascal Soriot will remain chief executive at AstraZeneca, after all? Shortly after reports from Israel emerged that he agreed in principle to become chief executive at Teva Pharmaceuticals, a fresh round of reports surfaced late last week that he will host the next AstraZeneca investor call. His tenure at AstraZeneca has been marked by setbacks since he arrived in 2012 and laid out an ambitious growth plan, partly to fend off a takeover by Pfizer.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • While this quote sounds rather British – “It’s difficult to have a constructive conversation with government if you are suing them,” says one unnamed source. – it shows they are still a bit ‘Americanized.’ I would have expected “One must observe that it’s difficult to have …” Ah, well, still deftly put.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X